Latest in: News

Tagworks paper on pretargeting using click chemistry in vivo

In a recent paper in the Journal of Nuclear Medicine, Tagworks, in collaboration with Austrialian biotech company Avipep, describes an alternative radioimmunotherapy strategy based on separate administration of the tumor-homing agent and a fast clearing radioactive probe. This way, the unwanted high renal retention of low-molecular weight radiometal tumor-homing agents can …
October 29, 2015

NanoNextNL awards two valorization grants to Tagworks

Tagworks Pharmaceuticals has received two valorization grants, €180,000 total, from NanoNextNL, the Dutch research and innovation program on nanotechnology. The grants will be used to take two of the company's core programs to the next level. One grant concerns Tagworks' antibody drug conjugate (ADC) technology and will be applied to further …
October 8, 2015

Tagworks and City of Hope secure US$ 465k ‘Breakthrough Award’ from US Department of Defense

For their proposal "Click chemistry-triggered activation of Antibody-Drug Conjugates", Tagworks Pharmaceuticals and the research group of professor Paul Yazaki at the Department of Immunology, City of Hope Beckman Research Institute in Duarte, CA, were awarded a US$465,000 Breakthrough Award through the Breast Cancer Research Program (BCRP) of the US Department …
July 2, 2015

Tagworks features in Medicines

The latest edition of Medicines, a Dutch journal on drug development, features Tagworks Pharmaceuticals in the start-up sections. The article by Rik Nijland appeared in Medicines 1, February 2015 (in Dutch) 24_25_med1_startup
March 10, 2015

Paper on improved antibody tag in Molecular Pharmaceutics

Developing an antibody tag with improved pharmacokinetics and stability allowed Tagworks to achieve increased tumor uptake of a radiolabeled pretargeting probe. Even though this adapted tag exhibited a slight loss in reactivity, its use in a antibody (CC49-TCO) conjugate demonstrated a longer clearance half-life, improved tumor accumulation and increased in …
September 5, 2014

Current Opinion in Chemical Biology features Tagworks review

Approaches that use in vivo chemistry to enable non-invasive molecular imaging and therapy are much sought after. Taking the recent achievements in pretargeted radioimmuno-imaging and -therapy in mice as a starting point, the Tagworks team discuss how the application scope of this approach can eventually be extended towards humans. Read …
September 5, 2014

Tagworks presents at Gordon Research Conference

Marc Robillard, CEO of Tagworks Pharmaceuticals has been invited to speak during the Gordon Research Conference on Organic Reactions and Processes, held from 13-18 July 2014 at Bryant University, Smithfield, RI. In his lecture entitled "In vivo Chemistry for Cancer Imaging and Therapy" Marc Robillard will present the company's R&D …
July 7, 2014

Tagworks and the University of Missouri-Columbia receive $ 585k NIH grant

Together with prof. Tom Quinn of the University of Missouri-Columbia, Tagworks succeeded in securing an Exploratory/Development grant from the US National Institutes of Health (NIH) Innovative Molecular Analysis Technologies (IMAT) program for the project "In vivo metal-free cycloaddition chemistry driven pretargeted cancer radiotherapy". The proposal was ranked in the top …
December 16, 2013

Click to release – Tagworks publishes new approach to selective bioorthogonal release

By modifying the fastest and highly selective click reaction, the inverse-electron-demand-Diels-Alder reaction, Tagworks has achieved selective bioorthogonal release. This holds promise for the chemically triggered release, and thus activation, of drugs from tumor-bound Antibody-Drug Conjugates (ADCs), which would greatly enhance the scope of suitable ADC targets. Published in: Angewandte Chemie …
November 26, 2013

Tagworks paper in Journal Nuclear Medicine

Tagworks' pretargeting technology can boost tumor/non-tumor ratios compared with conventional radioimmunoimaging and -therapy. Published in Journal Nuclear Medicine 2013, 54, 11, 1989-1995 doi:10.2967/jnumed.113.12.3745
October 7, 2013

Curious about what we do? Get in touch!


About    Our Technology   Pipeline    Join us    News    Contact

T +31 85 800 8550

Tagworks Pharmaceuticals BV
Toernooiveld 1
6525 ED  Nijmegen
The Netherlands

Stay updated

© Tagworks Pharmaceuticals, 2024 | Terms of use | Design by Ape to Zebra